296 related articles for article (PubMed ID: 31416774)
1. The impact of CFTR modulator therapies on CF airway microbiology.
Rogers GB; Taylor SL; Hoffman LR; Burr LD
J Cyst Fibros; 2020 May; 19(3):359-364. PubMed ID: 31416774
[TBL] [Abstract][Full Text] [Related]
2. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.
Saluzzo F; Riberi L; Messore B; Loré NI; Esposito I; Bignamini E; De Rose V
Cells; 2022 Apr; 11(7):. PubMed ID: 35406809
[TBL] [Abstract][Full Text] [Related]
3. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.
Harvey C; Weldon S; Elborn S; Downey DG; Taggart C
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408875
[TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
5. Changes in the Cystic Fibrosis Airway Microbiome in Response to CFTR Modulator Therapy.
Yi B; Dalpke AH; Boutin S
Front Cell Infect Microbiol; 2021; 11():548613. PubMed ID: 33816324
[TBL] [Abstract][Full Text] [Related]
6. An update on new and emerging therapies for cystic fibrosis.
Hudock KM; Clancy JP
Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
[TBL] [Abstract][Full Text] [Related]
7. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
Carbone A; Vitullo P; Di Gioia S; Conese M
Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895314
[TBL] [Abstract][Full Text] [Related]
8. Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages.
Gillan JL; Davidson DJ; Gray RD
Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303535
[TBL] [Abstract][Full Text] [Related]
9. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
10. CFTR: cystic fibrosis and beyond.
Mall MA; Hartl D
Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
[TBL] [Abstract][Full Text] [Related]
11. Important steps in the journey to highly effective CFTR modulator access for people with CF.
VanDevanter DR; Mayer-Hamblett N
J Cyst Fibros; 2019 Sep; 18(5):577-578. PubMed ID: 31500809
[No Abstract] [Full Text] [Related]
12. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Zhang S; Shrestha CL; Kopp BT
Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
[TBL] [Abstract][Full Text] [Related]
13. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy.
Saiman L
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3():S18-S26. PubMed ID: 31715086
[TBL] [Abstract][Full Text] [Related]
14. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
[TBL] [Abstract][Full Text] [Related]
15. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
16. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
Kunzelmann K; Mall M
Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
[TBL] [Abstract][Full Text] [Related]
17. Rapid therapeutic advances in CFTR modulator science.
Clancy JP
Pediatr Pulmonol; 2018 Nov; 53(S3):S4-S11. PubMed ID: 30289627
[TBL] [Abstract][Full Text] [Related]
18. Airway Inflammation and Host Responses in the Era of CFTR Modulators.
Keown K; Brown R; Doherty DF; Houston C; McKelvey MC; Creane S; Linden D; McAuley DF; Kidney JC; Weldon S; Downey DG; Taggart CC
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887484
[TBL] [Abstract][Full Text] [Related]
19. Discovery of CFTR modulators for the treatment of cystic fibrosis.
Lopes-Pacheco M; Pedemonte N; Veit G
Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
[TBL] [Abstract][Full Text] [Related]
20. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
